

## CURRICULUM VITAE ET STUDIORUM

NAME: Susanna MANDRUZZATO

PRESENT APPOINTMENT: Associate Professor of Immunology, Department of Surgery, Oncology and Gastroenterology, Oncology and Immunology Section, University of Padova, Italy.

### QUALIFICATIONS:

- Pharmaceutical Chemistry degree, 1989
- PhD in Oncology, University of Padova, 1999

### PREVIOUS APPOINTMENTS :

- Institute of General Pathology, University of Padova, Italy, 1989 - 1990
- Institute of Oncology, Chair of Immunology, University of Padova, Italy, 1990- 1994
- Investigator, Ludwig Institute for Cancer Research (Brussels Branch) - Brussels, Belgium 1994 -1997
- Assistant Professor of Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, 2006-2018

### POSTGRADUATE AWARDS AND FELLOWSHIPS:

- Fellowship "Italian consortium for antitumoral vectors" 1990 - 1992
- Fellowship "Italian association for cancer research" 1993 -1994
- Post doctoral fellowship : Training and Mobility of Researchers (TMR), 1996.
- Post-doctoral fellowship : ICGEB 1998-1999
- Post-doctoral fellowship, University of Padova. 2000-2001
- UICC post-doctoral fellowship, October 2003
- Collaborative research contract with Padova University, 2001-2003

### LEARNED SOCIETIES:

- CIP, CIMT Immunoguiding Program. Member of the steering Committee.
- SIICA, Italian Society of Immunology, Clinical Immunology and Allergology
- IMI, Italian Melanoma Intergroup

### MAJOR RESEARCH INTERESTS :

**-Role of adaptive immune response in different mouse models and implications for adoptive cell therapy.** (Rosato et al., *Int J Cancer*, 1992; Zanovello et al., *Cancer Immunol Immunother.*, 1992; Mandruzzato et al., *Pharmacological Res.*, 1192; Pollis et al. *Pharmacological Res.*, 1992; Rosato et al., *Leukemia/s*, 1992; Pollis et al. *Leukemia/s*, 1992; Mandruzzato et al., *Cancer Res.*, 1994; Rosato et al., *Int J Cancer*, 1995; Rosato et al., *Int J Cancer*, 1996)

**-Tumor antigens recognized by cytotoxic T lymphocytes: molecular identification and characterization of their role in cancer patients.** (Herman et al., *Immunogenetics*, 1996; Mandruzzato et al., *J. Exp. Med.*, 1997; Dalerba et al., *Int J Cancer*, 2001; Zambon et al., *Cancer*, 2001; Mandruzzato et al., *J Immunol*, 2002, Rosato et al., *Int J Cancer*).

**-Analysis of genes and miRNA expression in tumors and their role in tumor progression.** (Wang et al., *J Transl Med.*, 2004; Basil et al., *Cancer Res.*, 2006; Mandruzzato et al., *J Transl Med.*, 2006; Indraccolo et al., *J Immunol.*, 2007; Mandruzzato *Adv Exp Med Biol.*, 2007; Crende et al., *Am J Pathol.*, 2013; Pizzini et al., *BMC Genomics*, 2013; Bisognin et al., *Mol Onc.*, 2014; Perilli et al., *Oncotarget*, 2014; Perilli et al., *Genomics Data*, 2014).

**-Immune-evasion in cancer: role of myeloid-derived suppressor cells (MDSC).** (Bronte et al., *Immunol Invest*, 2006; Mandruzzato et al., *J. Immunol.*, 2009; Peranzoni et al., *Curr Opin Immunol* 2010; Marigo et al., *Immunity*, 2010; Chioda et al., *Cancer Metastasis Rev*, 2011; Solito et al., *J Leukoc Biol.*, 2011; Solito et al., *Blood*, 2011; Montero et al., *J Immunother.*, 2012; Walter et al., *Nature Medicine*, 2012; Solito et al., *Immunol Invest*, 2012; Ugel et al., *Cell Reports*, 2012; Zoso et al., *Eur. J. Immunol.*, 2014; Mazza et al. *Genomics Data*, 2014; Solito et al., *Annals of the NY Academy of Sc*, 2014; Damuzzo et al., *Cytometry part B*, 2015; Ugel et al., *J. Clin. Invest.*, 2015; Pinton et al., *Oncotarget*, 2015; Mandruzzato et al., *Cancer Immunol. Immunother.*, 2016; Solito et al., *J. of Pathol.*, 2017, Pinton et al., *OncoImmunology*, 2018).